<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_pneum-2019-0004_s_006_w2aab3b7b4b1b6b1aab1c16b1Aa"><h3>Background</h3><p>Chronic mucus hypersecretion is a common feature in chronic obstructive pulmonary disease (COPD) and is associated with epidermal growth factor (EGF) activity. Aberrant EGF and its receptor signalling can cause airway hyperproliferation, increase in mucous cell differentiation and mucus hyperproduction. Furthermore, it can also promote subepithelial fibrosis and excessive collagen deposition in COPD. The objective of this research was to investigate the plasma levels of EGF in smokers with COPD in comparison with clinically healthy smokers. In addition, the relationship between the plasma levels of EGF and clinical features was investigated.</p></sec><sec id="j_pneum-2019-0004_s_007_w2aab3b7b4b1b6b1aab1c16b2Aa"><h3>Methods</h3><p>A cross-sectional study included 82 clinically stable male patients with mild-to-very severe COPD (mean age: 64.5±8.6 years), and the control group consisted of 86 healthy male smokers (mean age: 61.6±9.5 years). To define COPD, we performed spirometry and classified COPD using Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification. We analyzed the levels of EGF by enzyme-linked immunosorbent assay in plasma.</p></sec><sec id="j_pneum-2019-0004_s_008_w2aab3b7b4b1b6b1aab1c16b3Aa"><h3>Results</h3><p>The mean serum levels of EGF were significantly lower in smokers with COPD than those in controls (69.30 and 83.82 pg/mL, respectively, p = 0.046). The plasma levels of EGF were significantly different (p = 0.004) between mild COPD and moderate-to-very severe COPD. There were no significant differences between the levels of EGF in plasma of spontaneous sputum producers (COPD patients) vs. nonsputum producers (p = 0.101) and between nonexacerbated COPD and exacerbated COPD patients(p = 0.138).</p></sec><sec id="j_pneum-2019-0004_s_009_w2aab3b7b4b1b6b1aab1c16b4Aa"><h3>Conclusions</h3><p>There is a significant difference in the plasma levels of EGF in male smokers with COPD as compared with male healthy smokers. Our findings suggest that the plasma levels of EGF may contribute to the pathogenesis of COPD.</p></sec></abstract>

BackgroundChronic mucus hypersecretion is a common feature in chronic obstructive pulmonary disease (COPD) and is associated with epidermal growth factor (EGF) activity. Aberrant EGF and its receptor signalling can cause airway hyperproliferation, increase in mucous cell differentiation and mucus hyperproduction. Furthermore, it can also promote subepithelial fibrosis and excessive collagen deposition in COPD. The objective of this research was to investigate the plasma levels of EGF in smokers with COPD in comparison with clinically healthy smokers. In addition, the relationship between the plasma levels of EGF and clinical features was investigated.MethodsA cross-sectional study included 82 clinically stable male patients with mild-to-very severe COPD (mean age: 64.5±8.6 years), and the control group consisted of 86 healthy male smokers (mean age: 61.6±9.5 years). To define COPD, we performed spirometry and classified COPD using Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification. We analyzed the levels of EGF by enzyme-linked immunosorbent assay in plasma.ResultsThe mean serum levels of EGF were significantly lower in smokers with COPD than those in controls (69.30 and 83.82 pg/mL, respectively, p = 0.046). The plasma levels of EGF were significantly different (p = 0.004) between mild COPD and moderate-to-very severe COPD. There were no significant differences between the levels of EGF in plasma of spontaneous sputum producers (COPD patients) vs. nonsputum producers (p = 0.101) and between nonexacerbated COPD and exacerbated COPD patients(p = 0.138).ConclusionsThere is a significant difference in the plasma levels of EGF in male smokers with COPD as compared with male healthy smokers. Our findings suggest that the plasma levels of EGF may contribute to the pathogenesis of COPD.

Decreased plasma epidermal growth factor (EGF) levels in patients with severe chronic obstructive pulmonary disease

Biomedical Sciences Post-Graduate Programme, Faculty of Medicine

Department of Anatomy, Faculty of Medicine

Department of Pulmonology and Respiratory Medicine, Faculty of Medicine

Department of Biochemistry, Molecular Biology, and Physiology, Faculty of Medicine

Pneumologia

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Nivelul plasmatic al factorului de creștere epidermal
(EGF) este scăzut la pacienții cu BPOC sever

BackgroundChronic mucus hypersecretion is a common feature in chronic obstructive pulmonary disease (COPD) and is associated with epidermal growth factor (EGF)...

Decreased plasma epidermal growth factor (EGF) levels in patients with severe chronic obstructive pulmonary disease

Article Category: Original Papers

Pubblicato online: 02 lug 2019

Pagine: 21 - 26

DOI: https://doi.org/10.2478/pneum-2019-0004

Parole chiave
COPD, plasma levels of EGF, smokers, mucous hypersecretion, exacerbation, spirometry

© 2019 Soemarwoto et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Decreased plasma epidermal growth factor (EGF) levels in patients with severe chronic obstructive pulmonary disease

Article Category: Original Papers

Pubblicato online: 02 lug 2019

Pagine: 21 - 26

DOI: https://doi.org/10.2478/pneum-2019-0004

Parole chiaveCOPD, plasma levels of EGF, smokers, mucous hypersecretion, exacerbation, spirometry

© 2019 Soemarwoto et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Parole chiave
COPD, plasma levels of EGF, smokers, mucous hypersecretion, exacerbation, spirometry